# Fentanyl Buccal Tablet or Morphine for Exertional Dyspnea in Cancer Patients

> **NCT04188418** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 150 (estimated)

## Conditions studied

- Hematopoietic and Lymphoid Cell Neoplasm
- Malignant Solid Neoplasm

## Interventions

- **DRUG:** Fentanyl Citrate Buccal Tablet
- **DRUG:** Morphine
- **OTHER:** Physical Performance Testing
- **OTHER:** Placebo Administration
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT04188418
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-23
- **Primary completion:** 2027-08-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-02-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04188418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04188418, "Fentanyl Buccal Tablet or Morphine for Exertional Dyspnea in Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04188418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*